Author Archives: Matrix and Metastasis

About Matrix and Metastasis

Matrix & Metastasis Lab | Targetting the Extracellular Matrix in Cancer

People: First Class Honours all round…

Thomas R. Cox, Dec 2019

I am delighted to share the news that our two wonderful Honours Students for 2019, Yordanos Setargew and Shivanjali Ratnaseelan have both been awarded First Class Honours from the School of Medical Sciences at UNSW Sydney. Yordanos for her project on “Targeting lysyl oxidase driven fibrosis in pancreatic ductal adenocarcinoma via copper inhibition” and Shivanjali for her project on the “Role of Extracellular Matrix Stiffness on Tumor Cell Response to Therapy”

Congratulations to both đŸ™‚


Publication: Targeting the lysyl oxidases in tumour desmoplasia

Thomas R. Cox, Nov 2019

Targeting the lysyl oxidases in tumour desmoplasia

Our recent review discussing the importance, and also the therapeutic potential of inhibiting the lysyl oxidase (LOX) family of enzymes as a stromal targeting therapy has just been published in Biochemical Society Transactions.

The Lysyl Oxidase (LOX) Family

The Lysyl Oxidase (LOX) family of enzymes

Continue reading

Award: St Vincent’s Clinic Foundation Award to Elysse

Thomas R. Cox, Nov 2019

I’m delighted to announce that Elysse from the Matrix and Metastasis Team has just been awarded the St Vincent’s Clinic Foundation K&A Collins Cancer Research Award.

Elysse_SVCF_AwardThe St Vincent’s Clinic Foundation was established in 1992 to further the educational and research objectives of St Vincent’s Clinic and the surrounding precinct. The Foundation provides much-needed seed funding towards real research projects for real people including medical, basic and multidisciplinary research. The Awards are given to support bright young researchers who can put their research into real-world practise to improve patient care and health outcomes for the community.

The award which was announced at the annual Sandra David Oration, will give Elysse the opportunity (and $50,000 of seed funding) to further her novel work to find new and effective treatments for breast cancer to improve the clinical care and outcomes for patients.

Continue reading

People: Research Assistant position available to start late 2019/early 2020

Thomas R. Cox, Oct 2019


We are seeking a full-time dedicated Research Assistant (RA) to come work with us.  The group combines the use of 3D models of cancer with novel state-of-the-art imaging approaches to reveal how the extracellular matrix (ECM) drives cancer progression and metastasis. Our mission is to establish targeting of the extracellular matrix as a viable therapeutic approach in the treatment of solid cancers.

Continue reading

News: Anti-fibrotic LOX family inhibitor program to progress to Phase Ib trial

Thomas R. Cox, Oct 2019

Following a successful Phase Ia trial of their oral anti-fibrotic systemic LOX inhibitor, Pharmaxis are now moving into a Phase Ib multiple ascending dose (MAD) study in healthy volunteers.

This is an exciting time for the Matrix and Metastasis team as we have been collaborating closely with Pharmaxis recently in developing a pre-clinical portfolio to help build a case for potentially transitioning this compound through to a clinical trial in pancreatic cancer patients. Pharmaxis is already seeking to progress this compound in the myelofibrosis space, and so working with our team, we are exploring the potential for this exciting anti-fibrotic compound in other cancer settings.

Pharmaxis Systemic LOX inhibitor

Continue reading

Publication: CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer

Thomas R. Cox, Oct 2019

CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer

Working together with A/Prof Paul Timpson’s lab, we are pleased to announce that our recent review on targetting CAFs in pancreatic cancer has just been published in Trends In Cancer.

In this work we explore how different aspects of CAF heterogeneity are defined and how these manifest in multiple cancers, with a focus on pancreatic ductal adenocarcinoma (PDAC).

Mechanisms of CAF Heterogeneity

Continue reading